摘要
目的 探讨基于乙型肝炎 (Hepatitisbvirus,HBV)核心抗原免疫优势细胞毒性T淋巴细胞 (CytotoxicTlympho cyte,CTL)表位的治疗性多肽抗原组分、结构以及在HBV转基因小鼠体内的免疫学功能。方法 用分子设计的理论和方法 ,设计基于HBV核心抗原免疫优势性CTL表位、Pre S2B细胞表位及破伤风类毒素通用TH 表位的治疗性多肽疫苗候选分子 ,经Merrifield固相多肽合成技术合成 ,经高效液相色谱 (HPLC)纯化、鉴定。以HBV转基因小鼠为试验对象 ,进行体内免疫学功能研究。结果 所设计治疗性多肽分子可在体诱导较强的抗原特异性CD8+ T细胞应答和适度的抗体反应 ,并抑制HBV特异性抗原的分泌和乙型肝炎病毒复制。结论 提示所设计基于HBV核心抗原免疫优势性CTL表位、Pre S2B细胞表位及破伤风类毒素通用TH 表位的多肽分子可作为乙型肝炎治疗性多肽疫苗候选分子。
Objective To investigate immunologically the function of therapeutic peptides based on HBV core antigen in HBV transgenic mice. M ethods Therapeutic peptides comprised of the immunodominant B and CTL e pitopes of HBV Pre S2 region and HBcAg, and the T helper epitope of teta nus toxo id were designed and synthesized. The immunological functions were studied in HB V transgenic mice. Results The results demonstrated that th e pe ptide could trigger vigorous HBV specific CD8 + CTL responses and induce HBV a ntigen secretion inhibition and HBV replication inhibition in HBV transgenic mic e. Conclusions The results provided that the therapeutic peptid es based on the immunodominant CTL and B epitopes of HBV core antigen and HBV Pre S2 region, and the T helper epitope of tetanus toxoid could be a pro mising syn thetic therapeutic polypeptide vaccine against hepatitis B virus infection.
出处
《免疫学杂志》
CAS
CSCD
北大核心
2003年第3期186-189,共4页
Immunological Journal
基金
国家"973"计划资助项目 (2 0 0 1CB5 1 0 0 0 1 )
